Compare CXW & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXW | IDYA |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.6B |
| IPO Year | 2001 | 2019 |
| Metric | CXW | IDYA |
|---|---|---|
| Price | $30.59 | $31.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | $41.80 | ★ $51.92 |
| AVG Volume (30 Days) | ★ 1.7M | 814.2K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.19 | 61.90 |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $2,211,182,000.00 | $218,710,000.00 |
| Revenue This Year | $22.27 | N/A |
| Revenue Next Year | $8.36 | $188.45 |
| P/E Ratio | $40.12 | ★ N/A |
| Revenue Growth | 12.72 | ★ 3024.43 |
| 52 Week Low | $15.74 | $26.81 |
| 52 Week High | $36.55 | $42.68 |
| Indicator | CXW | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 32.99 |
| Support Level | $28.54 | $29.74 |
| Resistance Level | $34.69 | $31.95 |
| Average True Range (ATR) | 1.42 | 1.50 |
| MACD | 0.06 | -0.22 |
| Stochastic Oscillator | 37.01 | 7.05 |
CoreCivic Inc is an owner and operator of private prisons and detention centers in the United States. It operates in three segments: Safety, Community, and Properties. The Community segment owns and operates residential reentry centers. The Properties segment owns properties for lease to third parties and government agencies. The vast majority of the company's revenue comes from the CoreCivic Safety segment which consists of correctional and detention facilities that are owned, or controlled via a long-term lease, and managed by the company, as well as those correctional and detention facilities owned by third parties but managed by CoreCivic.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.